Home / Stock ratings / XLV

ETF rating

State Street Health Care Select Sector SPDR ETF (XLV) ETF Rating & Analysis

As of November 20, 2026, MELANY rates State Street Health Care Select Sector SPDR ETF 71 out of 100 (Sector Leader). Its highest factor score is cost and structure at 98, and its lowest is regime fit at 44.

MELANY ratingRated 2026-11-20

XLV · composite score

71/100
Sector Leader
Nov 20
Rating date
Live price in the app →
Cost & Structure98
Trend & Structure72
Risk-Adj. Return53
Source basis SEC filings and live market dataDated snapshot

About State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund tracks health-care companies in the S&P 500 - pharmaceuticals, biotechnology, providers, and medical devices.

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why XLV scores 71/100

XLV's 8 factor scores run from 44 to 98, and 3 of them sit above its composite of 71. Here is how XLV breaks down.

Diversification56/100

How well the fund spreads risk across holdings rather than concentrating it.

Cost & Structure98/100

Expense ratio, size and how soundly the fund is built.

  • Very low cost, 0.08% expense ratio
Trend & Structure72/100

Direction and quality of the fund price trend.

  • Uptrend confirmed, price and 50-day above the 200-day MA
Income65/100

Distribution yield and how dependable that income has been.

Relative Strength92/100

How the fund is performing against its peer group and the broad market.

  • Leading the market, +11% vs SPY over 3 months
Momentum Quality64/100

Whether the current move looks durable or stretched.

Risk-Adj. Return53/100

Return weighed against volatility and drawdown.

Regime Fit44/100

How the current rate and market regime suits this kind of fund.

  • Risk-off tape is a headwind for cyclical exposure

Key risks for XLV

  • No acute structural risks flagged, standard market risk applies

XLV trade plan (Pro)

MELANY has a full position plan for State Street Health Care Select Sector SPDR ETF: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates XLV

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. State Street Health Care Select Sector SPDR ETF's 71/100 reflects etf factor weighting for its profile.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about XLV

Is State Street Health Care Select Sector SPDR ETF (XLV) a buy?

As of 2026-11-20, MELANY rated State Street Health Care Select Sector SPDR ETF Sector Leader with a composite score of 71/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

Should I buy State Street Health Care Select Sector SPDR ETF ETF?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates State Street Health Care Select Sector SPDR ETF (XLV) Sector Leader with a composite of 71/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the XLV ETF price forecast?

MELANY does not publish price targets or forecasts for XLV. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 71/100 across eight factors for State Street Health Care Select Sector SPDR ETF, and re-scores automatically as new price, earnings, and fundamental data arrive.

Is XLV ETF overvalued or undervalued?

MELANY's diversification factor currently reads 56/100 for State Street Health Care Select Sector SPDR ETF, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives XLV's read.

What price should I buy XLV at?

Rather than chasing the current price, MELANY computes a smart entry zone for XLV: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying XLV ETF?

The top risks MELANY currently flags for State Street Health Care Select Sector SPDR ETF: No acute structural risks flagged, standard market risk applies. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is State Street Health Care Select Sector SPDR ETF a good long-term investment?

For long-term durability the two factors that matter most are cost & structure, which MELANY scores 98/100 for State Street Health Care Select Sector SPDR ETF, and income, at 65/100. The 71/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will XLV ETF go up?

Nobody can promise a fund's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's trend & structure factor reads 72/100 for XLV right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this XLV rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores XLV as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, XLV included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.